Legal psilocybin therapy is available in a small but growing number of places. Oregon has been serving clients since 2023, Colorado is expected to open healing centers in 2025, and several international retreats operate legally in Jamaica and the Netherlands. Beyond those options, clinical trials at major research universities offer another path, though eligibility is limited.
Oregon: The First Legal Option in the U.S.
Oregon became the first U.S. state to offer regulated psilocybin services after voters approved Measure 109 in 2020. Licensed service centers are now operating, and any adult 21 or older can book a session without a diagnosis or prescription. The experience includes a preparation visit, a supervised dosing session lasting several hours, and an optional integration session afterward.
The cost is significant. A full course of psilocybin treatment in Oregon runs roughly $2,000 to $3,000, and no health insurance covers it. That price typically bundles the preparation appointment, the psilocybin product, the facilitator’s time during the dosing session (which can last six to eight hours), and at least one follow-up conversation. Some centers charge more depending on the level of therapeutic support included.
Colorado: Healing Centers Opening in 2025
Colorado voters passed Proposition 122 in 2022, making it the second state to legalize and regulate psilocybin for therapeutic use. The state began accepting license applications for cultivators, manufacturers, and healing center operators in early 2025. Centers could open as early as mid-2025, though early summer is considered more realistic given the lag between application and approval.
Licensed facilitators in Colorado will conduct supervised sessions using psilocybin, following a model similar to Oregon’s. Pricing hasn’t been widely established yet, but it will likely fall in a comparable range given the facilitator time and regulatory overhead involved.
Other U.S. State Programs
A few other states are building narrower programs. Washington State enacted a psilocybin therapy pilot through the University of Washington specifically for veterans and first responders. New Jersey signed legislation in early 2026 establishing a two-year pilot program at three hospitals. These are limited in scope and not open to the general public in the way Oregon’s program is.
Meanwhile, the FDA granted psilocybin breakthrough therapy designation for treatment-resistant depression in 2018 and for major depressive disorder in 2019. Phase 2/3 and Phase 3 clinical trials are underway, but federal approval is still estimated to be several years out, and even after approval, a schedule change and insurance coding would need to follow before psilocybin could be prescribed like a standard medication.
Decriminalization Is Not the Same as Therapy
You may have seen headlines about cities decriminalizing psilocybin. Oakland, Santa Cruz, San Francisco, Berkeley, and Arcata in California have all passed resolutions making personal possession the lowest law enforcement priority. So have Denver, Ann Arbor, Detroit, Seattle, and several other cities in Michigan and Washington State. But these resolutions don’t legalize anything or create a framework for therapeutic services. They simply tell local police not to prioritize arrests for personal use.
In Seattle, for example, the resolution explicitly did not alter city ordinances, municipal codes, or legalize any controlled substance. If you live in a decriminalized city, you won’t find a licensed therapist offering psilocybin sessions through that local policy alone. Legal therapeutic access requires the kind of state-level regulatory framework that Oregon and Colorado have built.
International Retreat Options
For people willing to travel, two countries stand out.
Jamaica never listed psilocybin under its Dangerous Drugs Act, so the substance remains unregulated rather than explicitly legal. Several retreat operations have built structured programs around this gap. MycoMeditations, one of the more established companies, runs eight-day retreats with a three-dose regimen designed by on-site therapists, increasing dosages across sessions. Each dosing day includes individual and group therapy drawing on depth psychology, somatic therapy, and transpersonal frameworks. About 30% of applicants are screened out during a detailed pre-screening process that excludes people with psychiatric diagnoses or medical conditions that could be aggravated by psilocybin. A private psychiatric practice in Kingston offers a more clinical nine-week protocol starting with microdoses every three days for eight weeks, followed by an optional higher-dose session in the office.
The Netherlands occupies a legal gray area. Psilocybin mushrooms are illegal there, but psilocybin truffles (which contain the same active compound) are legal and sold openly. Retreat centers operate within this framework, offering supervised experiences in controlled settings. One important caveat: Dutch law prohibits these centers from making medical claims about treating or curing health conditions. You can pay for a guided, supported experience, but it won’t be framed as treatment for depression or PTSD in any official sense.
Clinical Trials as a Path
If you have a specific condition like treatment-resistant depression, PTSD, or substance use disorder, a clinical trial may be an option. Johns Hopkins Center for Psychedelic and Consciousness Research in Baltimore has studied psilocybin for PTSD in patients taking antidepressants. NYU, UCSF, Yale, and other major universities have run or are running trials targeting depression, anxiety, and addiction. ClinicalTrials.gov lists active studies you can search by condition and location.
The advantage of a clinical trial is cost: participants typically pay nothing and receive highly structured care from trained clinicians. The disadvantage is limited availability. Many trials recruit small numbers of participants, have strict eligibility criteria, and cycle between recruiting and not recruiting. A study may be listed as active but not currently enrolling new patients.
What a Typical Session Looks Like
Regardless of where you go, the therapeutic model follows a consistent three-phase structure. First, you’ll have one or more preparation sessions where a therapist or facilitator reviews your mental health history, discusses your intentions, and sets expectations for the experience. This phase helps build trust with the person who will be guiding you.
The dosing session itself lasts several hours, often six or more. You’ll typically lie down in a comfortable room, sometimes with eyeshades and music, while the facilitator stays present to provide reassurance and help you navigate intense emotions. The facilitator doesn’t direct the experience so much as support you through it.
Afterward, integration sessions help you process what came up. This is where the therapeutic value is often consolidated, as you work with a therapist to connect insights from the experience to patterns in your daily life. Some programs include one integration session, others include several over the following weeks.
Costs and What Insurance Covers
Right now, no insurance plan in the U.S. covers psilocybin therapy. Oregon sessions cost $2,000 to $3,000. International retreats vary widely but often run $3,000 to $7,000 or more when you include travel and accommodation. Some underground facilitator networks charge $1,500 to $4,000 just for the connection, before the session itself.
When researchers surveyed people experienced with psychedelics about what they considered reasonable pricing, the average answer was about $400 to $500 for a full-day dosing session and around $78 per hour for preparation or integration appointments. The gap between those expectations and current market prices reflects the high cost of regulatory compliance, lengthy facilitator training, and the simple fact that a single client requires six or more hours of one-on-one attention during a dosing day.